[go: up one dir, main page]

WO2017035413A3 - Carbamate, ester, and ketone compounds for treatment of immune and inflammatory disorders - Google Patents

Carbamate, ester, and ketone compounds for treatment of immune and inflammatory disorders Download PDF

Info

Publication number
WO2017035413A3
WO2017035413A3 PCT/US2016/048795 US2016048795W WO2017035413A3 WO 2017035413 A3 WO2017035413 A3 WO 2017035413A3 US 2016048795 W US2016048795 W US 2016048795W WO 2017035413 A3 WO2017035413 A3 WO 2017035413A3
Authority
WO
WIPO (PCT)
Prior art keywords
carbamate
immune
ester
treatment
inflammatory disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2016/048795
Other languages
French (fr)
Other versions
WO2017035413A2 (en
Inventor
Jason Allan Wiles
Avinash S. Phadke
Milind Deshpande
Atul Agarwal
Dawei Chen
Venkat Rao GADHACHANDA
Akihiro Hashimoto
Godwin Pais
Qiuping Wang
Xiangzhu Wang
William Greenlee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Achillion Pharmaceuticals Inc
Original Assignee
Achillion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Achillion Pharmaceuticals Inc filed Critical Achillion Pharmaceuticals Inc
Publication of WO2017035413A2 publication Critical patent/WO2017035413A2/en
Publication of WO2017035413A3 publication Critical patent/WO2017035413A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I" and I'" or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduce the excessive activation of complement.
PCT/US2016/048795 2015-08-26 2016-08-25 Carbamate, ester, and ketone compounds for treatment of immune and inflammatory disorders Ceased WO2017035413A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562210190P 2015-08-26 2015-08-26
US62/210,190 2015-08-26

Publications (2)

Publication Number Publication Date
WO2017035413A2 WO2017035413A2 (en) 2017-03-02
WO2017035413A3 true WO2017035413A3 (en) 2017-03-30

Family

ID=58100998

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/048795 Ceased WO2017035413A2 (en) 2015-08-26 2016-08-25 Carbamate, ester, and ketone compounds for treatment of immune and inflammatory disorders

Country Status (1)

Country Link
WO (1) WO2017035413A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2016009438A0 (en) 2014-02-25 2016-09-30 Achillion Pharmaceuticals Inc Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders
AR105808A1 (en) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc AMIDA COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
WO2017035355A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of medical disorders
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
AR105809A1 (en) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
AR106018A1 (en) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
WO2017035351A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of medical disorders
EP3340982B1 (en) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
WO2017035361A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for the treatment of medical disorders
US10000516B2 (en) 2015-08-26 2018-06-19 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of medical disorders
TWI854164B (en) 2016-02-01 2024-09-01 美商百歐克斯製藥公司 Benzopyrazole compounds and analogues thereof
EP3589287B1 (en) 2017-03-01 2022-09-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
CN110603252A (en) 2017-03-01 2019-12-20 艾其林医药公司 Aryl, heteroaryl and heterocyclic pharmaceutical compounds for the treatment of medical disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
EP3661493A4 (en) 2017-08-02 2021-04-14 Achillion Pharmaceuticals, Inc. Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria
WO2020041301A1 (en) 2018-08-20 2020-02-27 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
US11814391B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
MX2021002640A (en) 2018-09-06 2021-07-16 Achillion Pharmaceuticals Inc Morphic forms of complement factor d inhibitors.
EP3856164B1 (en) 2018-09-25 2024-08-07 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
US12239645B2 (en) 2018-12-17 2025-03-04 Achillion Pharmaceuticals, Inc. Targeted dosing for the treatment of complement mediated disorders
JP2022518526A (en) * 2019-01-25 2022-03-15 ノッドセラ リミテッド Carbamate derivatives and their use
JP7635138B2 (en) 2019-03-22 2025-02-25 アキリオン ファーマシューティカルズ， インコーポレーテッド Pharmaceutical compounds for the treatment of complement-mediated disorders
US20250197403A1 (en) 2020-02-20 2025-06-19 Achillion Pharmaceuticals, Inc. Heteroaryl compounds for treatment of complement factor d mediated disorders
CN116437913A (en) 2020-09-23 2023-07-14 艾其林医药公司 Pharmaceutical compounds for use in the treatment of complement-mediated disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050228000A1 (en) * 2004-04-13 2005-10-13 Smallheer Joanne M Bicyclic heterocycles useful as serine protease inhibitors
US20050267108A1 (en) * 2001-12-13 2005-12-01 Hsing-Pang Hsieh Indole compounds
US20120295884A1 (en) * 2011-01-04 2012-11-22 Novartis Ag Complement pathway modulators and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050267108A1 (en) * 2001-12-13 2005-12-01 Hsing-Pang Hsieh Indole compounds
US20050228000A1 (en) * 2004-04-13 2005-10-13 Smallheer Joanne M Bicyclic heterocycles useful as serine protease inhibitors
US20120295884A1 (en) * 2011-01-04 2012-11-22 Novartis Ag Complement pathway modulators and uses thereof

Also Published As

Publication number Publication date
WO2017035413A2 (en) 2017-03-02

Similar Documents

Publication Publication Date Title
WO2017035413A3 (en) Carbamate, ester, and ketone compounds for treatment of immune and inflammatory disorders
EP3934652A4 (en) Compounds, compositions, and methods for the treatment of disease
MX2023002688A (en) Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders.
EP4656249A3 (en) Pyrazolopyrimidine derivatives as kinase inhibitor
WO2017087608A8 (en) Modulators of ror-gamma
WO2015200481A8 (en) Mnk inhibitors and methods related thereto
WO2015130842A3 (en) Ether compounds for treatment of complement mediated disorders
WO2016044556A3 (en) Arginine methyltransferase inhibitors and uses thereof
WO2017035353A8 (en) Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders
WO2016172496A8 (en) Lsd1 inhibitors and uses thereof
WO2016130920A3 (en) Lrrk2 inhibitors and methods of making and using the same
WO2016164675A8 (en) Substituted quinazoline compounds and methods of use thereof
EP3675859A4 (en) Compounds, compositions, and methods for the treatment of disease
WO2017075629A3 (en) Wee 1 kinase inhibitors and methods of making and using the same
WO2015168466A8 (en) Inhibitors of lysine specific demethylase-1
CA2983481A1 (en) Janus kinase inhibitor
WO2017001926A8 (en) Therapeutic inhibitory compounds
IL311677B1 (en) Bicyclic heterocyclyl derivatives as irak4 inhibitors
WO2017191130A3 (en) Arginase inhibitors and their therapeutic applications
WO2017001936A3 (en) Therapeutic inhibitory compounds
HK1247201A1 (en) Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
MX2017007607A (en) Inhibitors of cellular necrosis and related methods.
WO2020051532A3 (en) Macrocyclic compounds for the treatment of medical disorders
WO2016004413A3 (en) Gls1 inhibitors for treating disease
EP4081201A4 (en) Pharmaceutical composition for treatment or prevention of multiple inflammatory disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16840168

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16840168

Country of ref document: EP

Kind code of ref document: A2